Clinical Trial Update: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria [Phase 3]

View source ↗

Summary

This document reports a Phase 3 clinical trial evaluating eculizumab for paroxysmal nocturnal hemoglobinuria, with the trial status listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Paroxysmal Hemoglobinuria, Nocturnal | Phase 3 | Status: COMPLETED